Corrigendum to “Development and validation of Ran as a prognostic marker in stage I and stage II primary breast cancer” [Life Sci., 329 (2023) 121964]
Mohamed El‐Tanani(Ras al-Khaimah Medical and Health Sciences University), Philip S. Rudland(Cancer Research UK), Alaa A. A. Aljabali(Yarmouk University), Khaled Abdul‐Aziz Ahmed(Ras al-Khaimah Medical and Health Sciences University), Walhan Alshaer(Al-Ahliyya Amman University), Hamdi Nsairat(Al-Ahliyya Amman University), Abdalla Awidi(University of Jordan), Ismail Matalka(Jordan University of Science and Technology), Angela Platt‐Higgins(University of Liverpool), Ángel Serrano‐Aroca(Valencia Catholic University Saint Vincent Martyr), Shudong Zhang(Sinopec (China)), Murtaza M. Tambuwala(Ras al-Khaimah Medical and Health Sciences University), Vijay Mishra(Lovely Professional University), Kyle B. Matchett(University of Ulster)
Cited by 1
Related Papers
Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems
|Pharmaceutics|2018|661
siRNA: Mechanism of action, challenges, and therapeutic approaches
|European Journal of Pharmacology|2021|428
Synthesis of Gold Nanoparticles Using Leaf Extract of Ziziphus zizyphus and their Antimicrobial Activity
|Nanomaterials|2018|341
The Current Status of Interpenetrating Polymer Networks
|Polymers for Advanced Technologies|1996|276
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages
|International Journal of Pharmaceutics|2003|261